Novo Nordisk will continue to exploit the emerging importance of China in pharma research by establishing a new diabetes research foundation there.
The Danish pharma company is setting up a joint science research foundation with the Chinese Academy of Science (CAS). The collaboration will concentrate on diabetes and biopharmaceuticals research, including related fields and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology and drug delivery.... more
Novo Nordisk donation aids Chinese pharmaceutical development and WHO efforts to combat neglected diseases
Novo Nordisk today announced a scientific collaboration that will benefit both Chinese pharmaceutical development and WHO efforts to combat neglected diseases.
Effective 28 April 2008, Novo Nordisk will donate a licence to its small molecule compound library to the National Center for Drug Screening (NCDS) affiliated to Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The centre will use the library â€“ both the actual compounds and an associated database â€“ for screening activities to identify new drug candidates for infectious tropical diseases that affect people in poor countries.
The World Health Organization-based Special Programme for Research and Training in Tropical Diseases (TDR) will select targets and screens to support the identification of new drug candidates or leads for infectious tropical diseases, including malaria, tuberculosis, African sleeping sickness, dengue, Chagas disease, leishmaniasis, schistosomiasis, filariasis, onchocerciasis and soil-transmitted helminths. It will also bring in young scientists from developing countries, especially Africa, to be trained at the institute.... more